DDA Nepal’s Journey Toward a Stronger Drug Regulatory System: Targeting WHO Maturity Level 3 by 2027
Strengthening Nepal’s National Regulatory Authority
The Department of Drug Administration (DDA), Nepal, is making significant strides in strengthening the country’s pharmaceutical regulatory system. As the National Regulatory Authority (NRA), DDA plays a critical role in ensuring that medicines, vaccines, and other health products available in Nepal are safe, effective, and of high quality.
One of the key indicators of regulatory performance is the World Health Organization (WHO) Global Benchmarking Tool (GBT), which assesses the maturity of a country’s National Regulatory Authority.
Current Regulatory Maturity Status
At present, Nepal’s National Regulatory Authority is assessed at WHO Maturity Level 1 (ML-1).
Maturity Level 1 indicates that some regulatory system elements exist; however, they require further development and strengthening to function consistently and effectively.
The Roadmap Ahead
DDA Nepal has established an ambitious roadmap to improve its regulatory performance:
- Current Status: WHO Maturity Level 1 (ML-1)
- Target by 2027: Achieve WHO Maturity Level 3 (ML-3)
- 2027–2030: Sustain and continuously strengthen ML-3 performance
Achieving Maturity Level 3 will signify that Nepal has a stable, well-functioning, and integrated regulatory system capable of effectively overseeing medical products throughout their lifecycle.
What is WHO Maturity Level 3?
A National Regulatory Authority at Maturity Level 3 demonstrates:
- A stable and well-functioning regulatory system.
- Effective oversight of medicines, vaccines, medical devices, and other health products.
- Risk-based regulatory decision-making.
- Strong inspection, licensing, pharmacovigilance, and market surveillance systems.
- Compliance with internationally recognized regulatory standards.
- Continuous quality improvement and performance monitoring.
Why is Achieving ML-3 Important?
Reaching WHO Maturity Level 3 offers several benefits for Nepal:
- Improved public health through better assurance of medicine quality, safety, and efficacy.
- Greater public confidence in the national healthcare system.
- Enhanced regulatory efficiency, resulting in faster and more transparent regulatory decisions.
- Support for local pharmaceutical industries to meet international quality standards.
- Increased opportunities for international collaboration and regulatory reliance.
- Improved preparedness for public health emergencies and access to essential medical products.
DDA Nepal’s Commitment
To achieve ML-3, DDA Nepal is strengthening multiple regulatory functions, including:
- Product registration and marketing authorization
- Good Manufacturing Practice (GMP) inspections
- Quality control and laboratory capacity
- Pharmacovigilance and post-marketing surveillance
- Clinical trial oversight
- Regulatory governance and digital transformation
- Capacity building of regulatory professionals
These initiatives are aligned with WHO recommendations and Nepal’s long-term vision of building a robust, transparent, and internationally recognized regulatory system.
Looking Ahead
The transition from WHO Maturity Level 1 to Maturity Level 3 by 2027 represents a major milestone for Nepal’s healthcare and pharmaceutical sector. Sustaining this achievement through 2030 will further strengthen public trust, improve access to quality-assured medicines, and position Nepal as a country with a reliable and internationally credible regulatory authority.
The Department of Drug Administration’s commitment to regulatory excellence is an important step toward ensuring that every medicine reaching the people of Nepal meets the highest standards of quality, safety, and effectiveness.
